Add an Intranasal Corticosteroid to the Current Regimen
For this 66-year-old patient with persistent allergic symptoms despite montelukast 10 mg daily, the most effective next step is to add an intranasal corticosteroid (such as fluticasone propionate or mometasone furoate), as intranasal corticosteroids are significantly more effective than montelukast alone for allergic rhinitis symptom control. 1
Why Intranasal Corticosteroids Are the Priority
The 2017 Joint Task Force guidelines establish a clear hierarchy: intranasal corticosteroids demonstrate superior efficacy compared to leukotriene receptor antagonists (like montelukast) for allergic rhinitis 1. The evidence shows clinically meaningful differences in nasal symptom reduction, with intranasal corticosteroids consistently outperforming montelukast across multiple trials 1.
Montelukast was likely chosen initially because some patients prefer oral agents, but this preference comes at the cost of reduced efficacy 1. Since symptoms persist, escalation to more effective therapy is warranted.
The Combination Approach
Continue the montelukast and add an intranasal corticosteroid rather than switching entirely. Here's why:
- The patient is already tolerating montelukast well (given finasteride use, no drug interactions exist 2)
- Adding an intranasal corticosteroid to existing montelukast provides additive benefit 3
- Research shows combination therapy (intranasal corticosteroid + montelukast) produces better quality of life scores and faster symptom improvement than either agent alone 3
Specific Recommendations
Prescribe:
- Mometasone furoate 200 mcg intranasally once daily OR fluticasone propionate 200 mcg intranasally once daily
- Continue montelukast 10 mg daily in the evening 2
- Continue finasteride 5 mg (no interactions) 2
Timing: Intranasal corticosteroids can be administered morning or evening without regard to meals 1. Montelukast should continue in the evening as currently prescribed 2.
If Further Escalation Is Needed
Should symptoms remain inadequately controlled after 2-4 weeks on intranasal corticosteroid + montelukast:
Add a second-generation oral antihistamine (desloratadine 5 mg or levocetirizine 5 mg daily):
- Triple therapy (montelukast + intranasal corticosteroid + antihistamine) shows superior symptom control compared to dual therapy 4, 5, 6
- Montelukast-desloratadine combination reduces total nasal symptom scores significantly (baseline 7.7 → 3.04 with combination vs 3.74 with desloratadine alone) 4
- Montelukast-levocetirizine combination is particularly effective for nighttime symptoms 4, 6
Alternative: Combination Intranasal Spray
For moderate-to-severe symptoms, consider fluticasone propionate 200 mcg + azelastine 548 mcg combination spray instead of monotherapy intranasal corticosteroid 1. This single-device combination produces greater symptom reduction than either agent alone (TNSS reduction: -5.31 to -5.7 for combination vs -3.84 to -5.1 for fluticasone alone) 1. However, dysgeusia (bad taste) occurs in 2-13% of patients 1.
Critical Safety Consideration
Monitor for neuropsychiatric symptoms while continuing montelukast. Recent evidence highlights potential anxiety, depression, sleep disturbances, and behavioral changes with montelukast use 7, 8. At age 66, the risk may be lower than in children/adolescents, but vigilance remains important. If any neuropsychiatric symptoms emerge, discontinue montelukast immediately and rely on the intranasal corticosteroid ± antihistamine regimen.
What NOT to Do
- Don't add an oral antihistamine to montelukast alone without first trying an intranasal corticosteroid—this bypasses the most effective therapy 1
- Don't discontinue montelukast abruptly if it's providing partial benefit; add to it rather than switch 3
- Don't use first-generation antihistamines in this 66-year-old due to sedation and anticholinergic effects